These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
65 related articles for article (PubMed ID: 23953881)
1. Suppression of SERPINA1-albumin complex formation by galectin-3 overexpression leads to paracrine growth promotion of chronic myelogenous leukemia cells. Nakayama R; Kuroda J; Taniyama N; Yamamoto-Sugitani M; Wada S; Kiyota M; Mizutani S; Chinen Y; Matsumoto Y; Nagoshi H; Shimura Y; Kobayashi T; Horiike S; Sato K; Taniwaki M Leuk Res; 2014 Jan; 38(1):103-8. PubMed ID: 23953881 [TBL] [Abstract][Full Text] [Related]
2. Galectin-3 (Gal-3) induced by leukemia microenvironment promotes drug resistance and bone marrow lodgment in chronic myelogenous leukemia. Yamamoto-Sugitani M; Kuroda J; Ashihara E; Nagoshi H; Kobayashi T; Matsumoto Y; Sasaki N; Shimura Y; Kiyota M; Nakayama R; Akaji K; Taki T; Uoshima N; Kobayashi Y; Horiike S; Maekawa T; Taniwaki M Proc Natl Acad Sci U S A; 2011 Oct; 108(42):17468-73. PubMed ID: 21987825 [TBL] [Abstract][Full Text] [Related]
3. [Overexpression of Shp-2 is associated with the unlimited growth and apoptosis resistance of p210 bcr-abl-mediated chronic myeloid leukemia]. Zhu XZ; Yu YZ; Fang YM; Liang Y; Lü QH; Xu RZ Zhonghua Yi Xue Za Zhi; 2005 Jul; 85(27):1903-6. PubMed ID: 16255985 [TBL] [Abstract][Full Text] [Related]
4. Effect of bone marrow mesenchymal stem cells from blastic phase chronic myelogenous leukemia on the growth and apoptosis of leukemia cells. Han Y; Wang Y; Xu Z; Li J; Yang J; Li Y; Shang Y; Luo J Oncol Rep; 2013 Aug; 30(2):1007-13. PubMed ID: 23733230 [TBL] [Abstract][Full Text] [Related]
5. c-Jun blocks cell differentiation but not growth inhibition or apoptosis of chronic myelogenous leukemia cells induced by STI571 and by histone deacetylase inhibitors. Huang HM; Liu JC J Cell Physiol; 2009 Mar; 218(3):568-74. PubMed ID: 19006173 [TBL] [Abstract][Full Text] [Related]
6. Anti-angiogenesis effects of meisoindigo on chronic myelogenous leukemia in vitro. Xiao Z; Wang Y; Lu L; Li Z; Peng Z; Han Z; Hao Y Leuk Res; 2006 Jan; 30(1):54-9. PubMed ID: 15982734 [TBL] [Abstract][Full Text] [Related]
7. [The effect of anti-bcr-abl hammerhead ribozyme on bone marrow purging]. Wu Y; Chen YZ; Huang HF; Chen P; Lu LH Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Sep; 35(9):859-63. PubMed ID: 12958661 [TBL] [Abstract][Full Text] [Related]
8. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation. Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172 [TBL] [Abstract][Full Text] [Related]
9. In vitro effect of adenovirus-mediated human Gamma Interferon gene transfer into human mesenchymal stem cells for chronic myelogenous leukemia. Li X; Lu Y; Huang W; Xu H; Chen X; Geng Q; Fan H; Tan Y; Xue G; Jiang X Hematol Oncol; 2006 Sep; 24(3):151-8. PubMed ID: 16700092 [TBL] [Abstract][Full Text] [Related]
10. Rapamycin provides a therapeutic option through inhibition of mTOR signaling in chronic myelogenous leukemia. Li J; Xue L; Hao H; Han Y; Yang J; Luo J Oncol Rep; 2012 Feb; 27(2):461-6. PubMed ID: 21993902 [TBL] [Abstract][Full Text] [Related]
11. Berbamine: a novel inhibitor of bcr/abl fusion gene with potent anti-leukemia activity. Xu R; Dong Q; Yu Y; Zhao X; Gan X; Wu D; Lu Q; Xu X; Yu XF Leuk Res; 2006 Jan; 30(1):17-23. PubMed ID: 16023722 [TBL] [Abstract][Full Text] [Related]
12. Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells. Gottschalk S; Anderson N; Hainz C; Eckhardt SG; Serkova NJ Clin Cancer Res; 2004 Oct; 10(19):6661-8. PubMed ID: 15475456 [TBL] [Abstract][Full Text] [Related]
13. Establishment of a new Glivec-resistant chronic myeloid leukemia cell line, SNUCML-02, using an in vivo model. Park J; Kim KI; Koh Y; Won NH; Oh JM; Lee DS; Kim BK; Ahn KS; Yoon SS Exp Hematol; 2010 Sep; 38(9):773-81. PubMed ID: 20438801 [TBL] [Abstract][Full Text] [Related]
14. Dup-697, a specific COX-2 inhibitor, suppresses growth and induces apoptosis on K562 leukemia cells by cell-cycle arrest and caspase-8 activation. Peng HL; Zhang GS; Liu JH; Gong FJ; Li RJ Ann Hematol; 2008 Feb; 87(2):121-9. PubMed ID: 17999062 [TBL] [Abstract][Full Text] [Related]
15. [Effects of ST1571 on the development of dendritic cells derived from bone marrow mononuclear cells in patients with chronic myeloid leukemia]. Zheng SE; Jin J; Tong XM; Qian WB; Xue YQ Zhonghua Zhong Liu Za Zhi; 2006 Dec; 28(12):920-3. PubMed ID: 17533744 [TBL] [Abstract][Full Text] [Related]
16. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib. Zhang GS; Liu DS; Dai CW; Li RJ Am J Hematol; 2006 Apr; 81(4):242-55. PubMed ID: 16550520 [TBL] [Abstract][Full Text] [Related]
17. [Study of apoptosis induced by indomethacin in chronic myeloid leukemia]. Tu C; Zhang G; Lu H Zhonghua Xue Ye Xue Za Zhi; 1999 Jul; 20(7):362-5. PubMed ID: 11721434 [TBL] [Abstract][Full Text] [Related]
18. Bone marrow fibroblasts-conditioned medium regulates the proliferation of leukemic cells. Kubota T; Nagao T; Arimori S Tokai J Exp Clin Med; 1988 Feb; 13(1):45-51. PubMed ID: 3232161 [TBL] [Abstract][Full Text] [Related]